About
Oncolytic Peptide
Areas of Focus
Categories
Gene Therapy, RNA & Peptide TherapyNorway
Team (16)
Clinical Trials (9)
View allTotal Trials
9
As Lead Sponsor
8
As Collaborator
1
Total Enrollment
417
By Phase
PHASE2: 5PHASE1: 3PHASE1/PHASE2: 1
By Status
COMPLETED: 7RECRUITING: 1UNKNOWN: 1
Clinical Trials Pipeline9 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
Today
Hover over trial bars to see details
Recent Trials
NCT06651151Collaborator
NeoLIPA: Neoadjuvant LTX-315 in Combination with Pembrolizumab in Resectable Stage III/IV Melanoma
PHASE2Recruiting
27 participants
Started: Nov 1, 2024 · Completed: May 31, 2031
NCT04796194Lead Sponsor
Intratumoral Injection of LTX-315 in Combination With Pembrolizumab in Advanced Melanoma
PHASE2Unknown
20 participants
Started: Jun 1, 2021 · Completed: Dec 31, 2024
NCT03725605Lead Sponsor
LTX-315 and Adoptive T-cell Therapy in Advanced Soft Tissue Sarcoma (ATLAS-IT-04)
PHASE2Completed
6 participants
Started: Dec 28, 2018 · Completed: Oct 11, 2021
NCT01986426Lead Sponsor
LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab
PHASE1Completed
80 participants
Started: Nov 30, 2013 · Completed: Aug 31, 2018
NCT01803035Lead Sponsor
A Phase II Study to Evaluate the Efficacy and Safety of Two Doses of LTX-109 in Impetigo
PHASE2Completed
210 participants
Started: Feb 28, 2013 · Completed: Apr 30, 2014
Locations (1)
Headquarters
Oslo, Norway
Map
Loading map...